CSTLCastle Biosciences Inc
$22.91
$0.79
(3.57%)
Closed $22.91
$0.24
(1.05%)
After Hours
EarningsAug 3
Mkt Cap$670.9M
Vol305,332.00
DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire FRIENDSWOOD, Texas, June 25...
PR Newswire
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire FRIENDSWOOD, Texas, June 23, 2026 Stokes was...
PR Newswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire FRIENDSWOOD, Texas, June 19, 2026 FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq...
PR Newswire
Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire...
PR Newswire
Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics...
PR Newswire
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations
Castle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analysts...
MarketBeat
Castle Biosciences Q1 Earnings Call Highlights
Castle Biosciences (NASDAQ:CSTL) reported first-quarter 2026 revenue of $83.7 million, supported by continued growth in what management described as its "core revenue drivers," DecisionDx-Melanoma and TissueCypher. Founder, President and CEO Derek Maetzold said test report volumes for the company's...
MarketBeat
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Castle Biosciences Reports First Quarter 2026 Results
Castle Biosciences Reports First Quarter 2026 Results Castle Biosciences Reports First Quarter 2026 Results PR Newswire FRIENDSWOOD, Texas, May 6, 2026 Delivered Q1 2026 revenue of $83.7 millionQ1...
PR Newswire
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest CSTL News
ViewDecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
PR Newswire
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
PR Newswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Advertisement|Remove ads.